Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals.
To seek for a new valid biomarker using non-invasive specimens for the diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI), we carried out the detection of amyloid beta (Abeta) protein in urine. Ten-millilitre urine samples were first sedimented with trichloroacetic acid, and the pellets were resuspended for further analysis by Western blotting with anti-Abeta antibody. The detection sensitivity of the method was 40pg/ml. Rates of subjects positive for monomeric Abeta according to their clinical dementia rating (CDR) were 11.1% for CDR 0, 62.5% for CDR 0.5, 83.3% for CDR 1, 54.5% for CDR 2 and 0% for CDR 3. A single Abeta band relative to the CDR score reflects an alteration in the production, solubility and clearance of Abeta in the brain. Thus, the method could be used as both a diagnostic and monitoring tool in assessing AD and MCI patients during disease-modifying therapies.
Takata
Manabu
M
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Nakashima
Manabu
M
Takehara
Taro
T
Baba
Hideyo
H
Machida
Kazuyuki
K
Akitake
Yoshiharu
Y
Ono
Kazuhiko
K
Hosokawa
Masato
M
Takahashi
Mitsuo
M
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000652:urine*; D016229:Amyloid beta-Peptides / Q000652:urine*; D003072:Cognition Disorders / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000652:urine*; D012720:Severity of Illness Index
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)